These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 25867798)

  • 1. Hypophosphatemia is Associated with the Serial Administration of Triple-Dose Gadolinium to Patients for Brain MRI.
    Wolansky LJ; Cadavid D; Punia V; Kim S; Cheriyan J; Haghighi M; Cook SD
    J Neuroimaging; 2015; 25(3):379-83. PubMed ID: 25867798
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety of serial monthly administration of triple-dose gadopentetate dimeglumine in multiple sclerosis patients: preliminary results of the BECOME trial.
    Wolansky LJ; Haghighi MH; Sevdalis E; Cook SD; Sethi N; Liu J; Joseph G; Tulloch K; Cadavid D
    J Neuroimaging; 2005 Jul; 15(3):289-90. PubMed ID: 15951416
    [No Abstract]   [Full Text] [Related]  

  • 3. MRI demonstration of gadolinium deposition in bone after monthly triple-dose gadopentetate dimeglumine and correlation with frequency of hypophosphatemia.
    Bageac D; DeBevits JJ; Munbodh R; Kaplan J; Wu R; DiCamillo PA; Hu C; Wang Y; Karimeddini D; Naismith RT; Dhib-Jalbut S; Wolansky L
    Clin Imaging; 2021 Feb; 70():136-141. PubMed ID: 33161342
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The relationship between inflammation and atrophy in clinically isolated syndromes suggestive of multiple sclerosis: a monthly MRI study after triple-dose gadolinium-DTPA.
    Paolillo A; Piattella MC; Pantano P; Di Legge S; Caramia F; Russo P; Lenzi GL; Pozzilli C
    J Neurol; 2004 Apr; 251(4):432-9. PubMed ID: 15083288
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Monthly triple-dose gadolinium administration: potential associations with leukopenia, hypophosphatemia, and bone marrow T1 hyperintensity.
    Chen D; Wolansky I; Imitola J; Malchoff C; Wu R; Dhib-Jalbut S; Bulsara K; Wolansky L
    J Int Med Res; 2022 Feb; 50(2):3000605221076977. PubMed ID: 35118901
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A multi-centre longitudinal study comparing the sensitivity of monthly MRI after standard and triple dose gadolinium-DTPA for monitoring disease activity in multiple sclerosis. Implications for phase II clinical trials.
    Filippi M; Rovaris M; Capra R; Gasperini C; Yousry TA; Sormani MP; Prandini F; Horsfield MA; Martinelli V; Bastianello S; Kühne I; Pozzilli C; Comi G
    Brain; 1998 Oct; 121 ( Pt 10)():2011-20. PubMed ID: 9798753
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimizing brain MRI protocols in the follow-up of patients with multiple sclerosis T2-weighted MRI of the brain after the administration of gadopentetate dimeglumine.
    Taschner CA; Kirsch EC; Scheffler K; Wetzel SG; Schulte-Mönting J; Kappos L; Radü EW
    Magn Reson Imaging; 2005 Apr; 23(3):469-74. PubMed ID: 15862648
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and effectiveness of single- versus triple-dose gadodiamide injection- enhanced MR angiography of the abdomen: a phase III double-blind multicenter study.
    Thurnher SA; Capelastegui A; Del Olmo FH; Dondelinger RF; Gervás C; Jassoy AG; Keto P; Loewe C; Ludman CN; Marti-Bonmati L; Meusel M; da Cruz JP; Pruvo JP; Sanjuan VM; Vogl T
    Radiology; 2001 Apr; 219(1):137-46. PubMed ID: 11274548
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gadolinium dose optimisation in patients with multiple sclerosis: intra- and inter-individual comparisons.
    Stecco A; Migazzo E; Saponaro A; Scarabino T; Tesser F; Monaco F; Carriero A
    Eur J Radiol; 2006 Jan; 57(1):37-42. PubMed ID: 16040220
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety of gadolinium-based contrast material in sickle cell disease.
    Dillman JR; Ellis JH; Cohan RH; Caoili EM; Hussain HK; Campbell AD; Strouse PJ
    J Magn Reson Imaging; 2011 Oct; 34(4):917-20. PubMed ID: 21769966
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A preliminary study comparing the sensitivity of serial monthly enhanced MRI after standard and triple dose gadolinium-DTPA for monitoring disease activity in primary progressive multiple sclerosis.
    Filippi M; Rovaris M; Gasperini C; Capra R; Bastianello S; Kuhne I; Yousry TA
    J Neuroimaging; 1998 Apr; 8(2):88-93. PubMed ID: 9557146
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dose-toxicity relationship of gadoxetate disodium and transient severe respiratory motion artifact.
    Davenport MS; Bashir MR; Pietryga JA; Weber JT; Khalatbari S; Hussain HK
    AJR Am J Roentgenol; 2014 Oct; 203(4):796-802. PubMed ID: 25055154
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serial gadolinium-DTPA of spinal cord MRI in multiple sclerosis: triple vs. single dose.
    Yousry I; Filippi M; Walther E; Gasperini C; Capra R; Yousry TA
    Magn Reson Imaging; 2000 Nov; 18(9):1183-6. PubMed ID: 11118774
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gadolinium-based contrast exposure, nephrogenic systemic fibrosis, and gadolinium detection in tissue.
    Wiginton CD; Kelly B; Oto A; Jesse M; Aristimuno P; Ernst R; Chaljub G
    AJR Am J Roentgenol; 2008 Apr; 190(4):1060-8. PubMed ID: 18356456
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incidence of immediate gadolinium contrast media reactions.
    Prince MR; Zhang H; Zou Z; Staron RB; Brill PW
    AJR Am J Roentgenol; 2011 Feb; 196(2):W138-43. PubMed ID: 21257854
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gadolinium-containing magnetic resonance imaging contrast and nephrogenic systemic fibrosis: a case-control study.
    Kallen AJ; Jhung MA; Cheng S; Hess T; Turabelidze G; Abramova L; Arduino M; Guarner J; Pollack B; Saab G; Patel PR
    Am J Kidney Dis; 2008 Jun; 51(6):966-75. PubMed ID: 18501784
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety of the long-time monthly triple dose of a Gd-based contrast agent.
    Sardanelli F; Mancardi G; Filippi M
    Eur Radiol; 2003 Dec; 13 Suppl 4():L243-4. PubMed ID: 15018197
    [No Abstract]   [Full Text] [Related]  

  • 18. Progressive increase of T1 signal intensity of the dentate nucleus on unenhanced magnetic resonance images is associated with cumulative doses of intravenously administered gadodiamide in patients with normal renal function, suggesting dechelation.
    Errante Y; Cirimele V; Mallio CA; Di Lazzaro V; Zobel BB; Quattrocchi CC
    Invest Radiol; 2014 Oct; 49(10):685-90. PubMed ID: 24872007
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics and imaging properties of Gd-EOB-DTPA in patients with hepatic and renal impairment.
    Gschwend S; Ebert W; Schultze-Mosgau M; Breuer J
    Invest Radiol; 2011 Sep; 46(9):556-66. PubMed ID: 21623212
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Change of serum phosphate level and clinical outcome of hypophosphatemia in massive burn patient.
    Yang HT; Yim H; Cho YS; Kim D; Hur J; Kim JH; Lee BC; Seo CH; Chun W
    J Trauma Acute Care Surg; 2012 Nov; 73(5):1298-302. PubMed ID: 23117386
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.